NERV

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2021 Results - Earnings Call Transcript

Minerva (NERV) Soars on Promising Schizophrenia Study Data

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

NERV Stock: Over 25% Increase Pre-Market Explanation

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021